Scholarlink

<p>Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with limited treatment options in the metastatic setting. We performed integrative transcriptomic analyses of TCGA and COMETE datasets and identified <i>BUB1</i>, a mitotic checkpoint kinase and prototypical non-oncogene addiction (NOA) factor, as significantly upregulated in metastatic PPGLs. We validated <i>BUB1</i> overexpression in primary tumour tissues using RT-qPCR and subsequently conducted functional studies in the human phaeochromocytoma-derived hPheo1 cell line. Genetic silencing of <i>BUB1</i> or its pharmacological inhibition with BAY1816032 significantly reduced cell viability, colony formation, migration, and invasion. Both interventions also decreased phosphorylation of histone H2A at threonine 120, a direct downstream target of BUB1 kinase activity. In migration and invasion assays, <i>BUB1</i> inhibition impaired motility and reduced expression of the epithelial-to-mesenchymal transition (EMT) markers N-cadherin and vimentin. These findings provide the first demonstration of <i>BUB1</i> overexpression in metastatic PPGL tissues. Preclinical evidence suggests that hPheo1 cells depend on <i>BUB1</i> for growth, genome stability, and invasive behaviour. These findings nominate <i>BUB1</i> as a candidate vulnerability and putative biomarker, warranting validation in larger, multi-institutional cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

BUB1 as a candidate non-oncogene addiction vulnerability in metastatic phaeochromocytoma/paraganglioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Marziehsadat Ahmadi,
  • Seyed Jalal Zargar,
  • Hussam Alkaissi,
  • Hans K. Ghayee,
  • Karel Pacak,
  • Pouria Jandaghi,
  • Daniel Auld

摘要

Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with limited treatment options in the metastatic setting. We performed integrative transcriptomic analyses of TCGA and COMETE datasets and identified BUB1, a mitotic checkpoint kinase and prototypical non-oncogene addiction (NOA) factor, as significantly upregulated in metastatic PPGLs. We validated BUB1 overexpression in primary tumour tissues using RT-qPCR and subsequently conducted functional studies in the human phaeochromocytoma-derived hPheo1 cell line. Genetic silencing of BUB1 or its pharmacological inhibition with BAY1816032 significantly reduced cell viability, colony formation, migration, and invasion. Both interventions also decreased phosphorylation of histone H2A at threonine 120, a direct downstream target of BUB1 kinase activity. In migration and invasion assays, BUB1 inhibition impaired motility and reduced expression of the epithelial-to-mesenchymal transition (EMT) markers N-cadherin and vimentin. These findings provide the first demonstration of BUB1 overexpression in metastatic PPGL tissues. Preclinical evidence suggests that hPheo1 cells depend on BUB1 for growth, genome stability, and invasive behaviour. These findings nominate BUB1 as a candidate vulnerability and putative biomarker, warranting validation in larger, multi-institutional cohorts.